Nymox Pharmaceutical Corporation has continued to successfully expand its broad, worldwide patent portfolio in support of its proprietary product development programs. The company offered investors an update regarding its U.S. Phase 2 study of its proprietary drug, NX-1207, for the treatment of benign prostatic hyperplasia (BPH). The phase 2 study is nearing completion, and the company anticipates the reporting of final results and statistical analysis for the study within the next few weeks.

Nymox recently provided an outline on the outstanding potential the company’s proprietary drug, NX-1207, has for the treatment of the relatively common condition known as enlarged prostate, or benign prostatic hyperplasia (BPH). Clinical trials show that the NX-1207 treatment for BPH has shown a superior safety and efficiency profile compared to those reported for current FDA approved BPH treatments.

Nymox was recently able to confirm that its experimental, enlarged-prostate treatment was more effective than the widely used drug finasteride in a midstage study. Results of 5 follow-up studies of available subjects from NX-1207 clinical trials also showed evidence of a number of benefits from NX-1207 treatment for up to 3 ½ years from the date of treatment.

Let us hear your thoughts: Nymox Pharmaceutical Corp. Message Board